---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-26-000012"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:20:24.161003+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q4 2025 revenue $209.8M, net loss $7.9M; reiterates 2026 guidance

## Summary
- GAAP net loss $7.9M ($0.08 loss per share); adjusted EPS $0.04.
- Revenue $209.8M roughly flat YoY; hereditary cancer testing volume +9%, GeneSight +9%, prenatal -6%.
- Full-year 2025 revenue $824.5M down 2%; reiterates 2026 revenue guidance $860-880M.
- Adjusted EBITDA $14.3M in Q4; company expects 2026 adjusted EBITDA $37-49M.
- Plans to launch Precise MRD in March 2026, AI-enabled Prolaris in Q2 2026, FirstGene in H2 2026.

## SEC filing metadata
- accession: 0000899923-26-000012
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992326000012/0000899923-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992326000012/mygn-20260223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-26-000012
- JSON: https://secwatch.observer/filing/0000899923-26-000012.json
- Plain text: https://secwatch.observer/filing/0000899923-26-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.